Data Supportive of KidneyIntelX Utility in Minorities and Veterans to Be Presented at the National Kidney Foundation Spring Clinical Meeting
LONDON and SALT LAKE CITY, April 12, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that two scientific presentations have been accepted at the upcoming National Kidney Foundation Spring Clinicals Conference taking place in Austin, Texas (April 11-15). The studies entitled the “Impact of KidneyIntelX testing on novel medication prescription in a diverse patient population” and “Diabetic kidney disease epidemiology in US veterans” show the importance of using KidneyIntelX bioprognosis in early stage kidney disease and diabetes patients to blunt the effects of health inequity, help guide proper drug prescription to patients in need, and support established clinical guidelines to slow or stop unnecessary progression to late stage kidney disease, kidney failure and dialysis.
- The webinar is now on-demand and available on www.kidneyintelx.com or via this link .
- National Kidney Foundation Clinical Spring Conference Data Presentations Include:
KidneyIntelX was recently introduced into the Wake Forest-Atrium Health System to predict progressive decline in kidney function. - The KidneyIntelX risk score identified those patients at highest risk which resulted in appropriately selecting SGLT2-inhibitors for the right patients.
- The data will be showcased from April 12-14 in the Poster Hall at the Austin Convention Center and the abstract is now online at the NKF website.